A phase II study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy showed that a novel monoclonal antibody, known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body.
Cleveland Clinic Abu Dhabi, in collaboration with experts from Cleveland Clinic in the U.S., performed the world’s first remotely conducted transcontinental robotic-assisted focal therapy for prostate cancer.
